Loading
Life sciences · Journal article
Frontiers in Immunology · October 30, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Immunotherapy has emerged as a crucial component in the treatment of non-small cell lung cancer (NSCLC). Nevertheless, interindividual variability in efficacy, along with both primary and acquired resistance, as well as immune-related adverse events, continue to limit the benefits for patients. The gut microbiota and its associated metabolites are believed to play a significant role in pulmonary immune regulation via the gut–lung axis, with alterations in this system being associated with NSCLC development and progression, as well as the outcomes of immunotherapy. This review summarizes the key features of gut microbial and metabolic profiles in patients with NSCLC, focusing particularly on the mechanisms by which short-chain fatty acids, bile acids, gut microbiota-associated Trp metabolites, and other microbial metabolites may influence the tumor immune microenvironment and responses to immunotherapy. Furthermore, we consider their potential value in supporting NSCLC diagnosis, prognostic assessment, and treatment-response prediction. Therapies aimed at targeting metabolic pathways, fecal microbiota transplantation, dietary interventions, and microbiome-based preparations present additional avenues for enhancing the efficacy of NSCLC immunotherapy and managing treatment-related toxicity. However, current evidence primarily stems from small clinical studies and animal models, while methodological discrepancies and limited causal evidence impede clinical translation. Future research that integrates longitudinal multi-omics analyses, metabolic tracing, and controlled clinical trials is essential to elucidate the clinical significance of the gut microbiota-metabolite axis in NSCLC immunotherapy and precision medicine.